Search for: "Madhulika Vishwanathan"
Results 1 - 10
of 10
Sort by Relevance
|
Sort by Date
28 Sep 2015, 9:58 am
It is not free to access so the IPKat cannot post a functioning link, but readers with access should be able to find it readily.Indian Patent Office rejects Pfizer patent application for Tofacitinib Spicy IP reports in a two-part blogpost by Madhulika Vishwanathan (here and here) that the Indian Patent Office has rejected a Pfizer application for a single stereoisomer of the rheumatoid arthritis drug Tofacitinib, on grounds of anticipation by prior… [read post]
2 Apr 2013, 10:33 am
The generic v. innovator battle has moved on to anti-diabetic drugs, with Glenmark has launched a cheaper generic version of pharma multinational Merck’s blockbuster anti-diabetes drug Januvia (Sitagliptin phosphate), as reported by Madhulika Vishwanathan here. [read post]
18 Feb 2013, 12:46 am
Madhulika reported that the Patent Office revoked Pfizer’s patent on Sunitib- an exorbitantly priced drug. [read post]
29 Jan 2013, 10:44 am
(see here and here) Finally, this review ends with extending a warm welcome to our 3 new Fellows, Anubha, Gopika and Aparajita, all bright young minds from NLUs, as well as Madhulika Vishwanathan, the new Spicy IP team member, all of whom would undoubtedly prove to be invaluable assets to the team in the days to come. [read post]
27 Jan 2013, 3:53 pm
Madhulika Vishwanathan is a registered Indian patent agent and has a Masters in Pharmacology from ICT, Mumbai. [read post]
15 Jan 2013, 1:45 am
In light of the recent decision to issue compulsory licenses for three anti-cancer drugs, Madhulika Vishwanathan brings us her third submission for our SpicyIP Fellowship application. [read post]
31 Dec 2012, 11:41 pm
Next in line is a guest post by Madhulika Vishwanathan in the Spicy IP Fellowship Post Series, wherein she has referred to few landmark judgments in 2012 pertaining to the Indian pharmaceutical patent industry, including the grant of compulsory license to Natco Pharma, revocation of the Sunitinib patent owned by Pfizer/Sugen, the Roche-Cipla patent infringement suit, revocation of India’s first pharmaceutical product patent etc. [read post]
31 Dec 2012, 1:52 pm
As 2012 draws to a close, Madhulika Vishwanathan brings us a concise review of the year that was, for the Indian pharmaceutical landscape. [read post]
25 Dec 2012, 8:08 am
Another guest post in the Fellowship series followed forth, this time by Madhulika Vishwanathan, an experienced patent agent, critiquing the Guidelines for Processing of Patent Applications relating to Traditional Knowledge and Biological Material. [read post]
23 Dec 2012, 1:03 am
Madhulika Vishwanathan brings our attention to the Dec 18th announcement of the final version of the Guidelines for Processing of Patent Applications relating to Traditional Knowledge and Biological material. [read post]
